Sch-42495 racemate |
رقم الكتالوجGC31318
One-Click Copy Product Info
|
زميل السباق Sch-42495 هو زميل السباق SCH 42495.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 145841-10-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sch-42495 racemate is the racemate of Sch-42495. Sch-42495 is a novel neutral metalloendopeptidase (NEP) inhibitor. Sch-42495 is the orally active ethylester prodrug of SCH 42354.
SCH 42354 selectively inhibits hydrolysis of leu-enkephalin and ANF (IC50 of 8.3 and 10.0 nM, respectively) in vitro[1].
Plasma levels of exogenous atrial natriuretic factor (ANF) are augmented and ANF clearance from plasma is delayed by oral Sch-42495 (3 to 30 mg/kg) in normotensive rats. Plasma ANF levels in volume expanded rats are higher in Sch-42495-treated rats. Diuretic and natriuretic effects of ANF are increased in rats treated with Sch-42495. In Dahl-S hypertensive rats, Sch-42495 (1 to 10 mg/kg orally) produces falls in blood pressure of a magnitude similar to that observed in DOCA-Na hypertensive rats. Significant hypotensive activity is observed 18 h after a single 10 mg/kg oral dose in Dahl-S hypertensive rats. In DOCA-Na hypertensive rats, a single dose of Sch-42495 significantly decreases cardiac output and does not lower systemic vascular resistance, a profile similar to that of ANF[1]. Spontaneously hypertensive rats (SHR) aged 9 to 10 weeks are injected with either Streptozotocin (45 mg/kg) or citrate buffer and randomized to receive either Captopril (25 mg/kg BID), Sch-42495 (30 mg/kg BID), S21402 (25 or 50 mg/kg BID), or vehicle by gavage for 4 weeks. A group of diabetic SHR is also allocated to receive the combination of Sch-42495 (30 mg/kg BID) and Captopril (25 mg/kg BID). The degree of renal NEP inhibition is determined by autoradiography, and plasma renin activity (PRA) is determined by radioimmunoassay. In nondiabetic SHR, S21402 and Captopril are equally effective. Relative heart weight decreases in parallel to the changes in blood pressure. Renal NEP is clearly inhibited (70% to 92%; P
[1]. Watkins RW, et al. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor. Am J Hypertens. 1993 May;6(5 Pt 1):357-68. [2]. Tikkanen T, et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension. 1998 Oct;32(4):778-85.
Animal experiment: | Rats[2] Streptozotocin-injected and citrate buffer–injected SHR are randomly allocated to receive by gavage Captopril Captopril (25 mg/kg BID in distilled water), Sch-42495 (30 mg/kg BID in 5% arabic gum), S21402 at 2 different doses (25 mg/kg BID or 50 mg/kg BID in 5% arabic gum), or vehicle for 4 weeks starting on the day of Streptozotocin or buffer injection. The choice of the 2 doses of S21402 is based on previous findings suggesting that sufficient renal NEP inhibition, comparable to 30 mg/kg of Sch-42495, may be obtained with 25 mg/kg of S21402, while 50 mg/kg of S21402 is needed to provide equipotent angiotensin I pressor response inhibitory efficacy compared with 25 mg/kg of Captopril. A group of diabetic SHR is also allocated to receive the combination of Sch-42495 (30 mg/kg BID) and Captopril (25 mg/kg BID) by gavage. |
References: [1]. Watkins RW, et al. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor. Am J Hypertens. 1993 May;6(5 Pt 1):357-68. | |
| Cas No. | 145841-10-7 | SDF | |
| Canonical SMILES | CSCC[C@@H](C(OCC)=O)NC(C(CSC(C)=O)CC1=CC=CC=C1C)=O | ||
| Formula | C20H29NO4S2 | M.Wt | 411.58 |
| الذوبان | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4297 mL | 12.1483 mL | 24.2966 mL |
| 5 mM | 485.9 μL | 2.4297 mL | 4.8593 mL |
| 10 mM | 243 μL | 1.2148 mL | 2.4297 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)